Market Indices
Sector Heatmap
CLYM — Climb Bio, Inc. Common Stock
NasdaqClimb Bio, Inc. Common Stock
- O
- 11.29
- H
- 11.29
- L
- 10.73
- V
- 1.57M
CLYM — Latest News & Headlines
11 Stories$CLYM stock is down 14% today. Here's what we see in our data. - Quiver Quantitative
$CLYM stock is down 14% today. Here's what we see in our data. Quiver Quantitative
Preliminary data from a kidney disease drug study were selected for an October talk. - Stock Titan
Preliminary data from a kidney disease drug study were selected for an October talk. Stock Titan
Biotech Stocks Widely Dive. Here Are The Hardest Hit. - Investor's Business Daily
Biotech Stocks Widely Dive. Here Are The Hardest Hit. Investor's Business Daily
The Technical Signals Behind (CLYM) That Institutions Follow - Stock Traders Daily
The Technical Signals Behind (CLYM) That Institutions Follow Stock Traders Daily
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $32 - Moomoo
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $32 Moomoo
Options for 70,000 shares were exercised at $1.29–$7.89 in Climb Bio (CLYM). - Stock Titan
Options for 70,000 shares were exercised at $1.29–$7.89 in Climb Bio (CLYM). Stock Titan
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Nigeria
Form 4 Climb Bio Inc For: 1 October By Investing.com Investing.com Nigeria
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com Nigeria
Climb Bio to present Phase 2 data on kidney disease therapies Investing.com Nigeria
Climb Bio to Present Preliminary Phase 2 Budoprutug Data in Primary Membranous Nephropathy at ASN Kidney Week 2026 - Quiver Quantitative
Climb Bio to Present Preliminary Phase 2 Budoprutug Data in Primary Membranous Nephropathy at ASN Kidney Week 2026 Quiver Quantitative
Raymond James adds Climb Bio stock to favorites list on drug potential - Investing.com India
Raymond James adds Climb Bio stock to favorites list on drug potential Investing.com India
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com India
Climb Bio to present Phase 2 data on kidney disease therapies Investing.com India